<DOC>
	<DOCNO>NCT01274455</DOCNO>
	<brief_summary>Near 85 % patient pancreatic adenocarcinoma diagnose locally advanced and/or metastatic unresectable tumor . In patient chemotherapy ( gemcitabine ) give palliative therapy . Aim present study evaluate feasibility , tolerance antitumor effect repeat intratumoral injection gene therapy product ( antitumor chemo sensitize effect ) combine gemcitabine patient unresectable pancreatic carcinoma .</brief_summary>
	<brief_title>Gene Therapy Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description>This gene therapy open non randomize phase I trial advance and/or metastatic pancreatic cancer patient . The protocol base administration increase dos plasmid DNA pre-complexed PEI ( polyethylenimine - non-viral vector ) encode two gene ( somatostatin receptor subtype 2 name sst2 deoxycitidine kinase : : uridylmonophosphate kinase name dck : :umk ) exhibit complementary therapeutic effect . Both transgene induce antitumor bystander effect render gemcitabine treatment efficient . Intratumor injection gene therapy product ( CYL-02 ) perform transgastric transduodenal route endoscopic ultrasound guidance . Each injection follow standard gemcitabine IV administration every week ( 1000 mg/m2 ) . Two intratumor injection dose CYL-02 administer one month interval . Four increase dos ( 125 µg , 250 µg , 500 µg 1 mg ) test group 6 patient . The primary objective : evaluation local pancreatic general tolerance ; secondary objective : possible tumor volume regression , secondary respectability , evaluation transgene biodistribution .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patient pancreatic adenocarcinoma histologically proven and/or solid pancreatic mass associate multiple metastatis pancreatic origin ( histologically proven ) Patient non resectable pancreatic adenocarcinoma ( preoperative CTscan and/or endoscopic ultrasound evaluation ) Pancreatic tumor could evaluate endoscopic ultrasound ( digestive stenosis , gastrectomy ) Patient contraindication général anaesthesia . Karnofsky index &gt; = 70 % Written informed consent give Exclusion period another clinical trial research protocol . Patient unable read understand information/consent formula unable decide alone participation trial Patient tutelage Pregnant woman able procreate without contraception . Patient pancreatic cystic tumor pancreatic pseudocyst . Patient pancreatic tumor different adenocarcinoma ( endocrine , metastasis ) . Patient contraindication Gemzar® : Hypersensitivity Gemcitabine . Decision radiotherapy Granulocytes &lt; 1000/mm3 Thrombocytes &lt; 100 000/mm3 Patient efficiently treat jaundice ( biliary stent bypass ) present time diagnosis Contraindication fine needle aspiration biopsy endoscopic ultrasound ( hemostasis trouble ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gene therapy</keyword>
	<keyword>pancreatic carcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>endoscopic ultrasound</keyword>
</DOC>